A head‐to‐head comparison of risankizumab and ixekizumab for genital psoriasis: a real‐life, 24‐week, prospective study.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/jdv.17880

留言 (0)

沒有登入
gif